[1] Dyson JK, Beuers U, Jones D, et al. Primary sclerosing cholangitis. Lancet, 2018.
[2] Weismuller TJ, Trivedi PJ, Bergquist A, et al. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate with Course of Primary Sclerosing Cholangitis. Gastroenterology, 2017, 152: 1975-1984.
[3] Jiang X, Karlsen TH. Genetics of primary sclerosing cholangitis and pathophysiological implications. Nat Rev Gastroenterol Hepatol, 2017, 14: 279-295.
[4] Ji SG, Juran BD, Mucha S, et al. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nat Genet, 2017, 49: 269-273.
[5] Folseraas T, Melum E, Rausch P, et al. Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol, 2012, 57: 366-375.
[6] Maroni L, Hohenester SD, van de Graaf S, et al. Knockout of the primary sclerosing cholangitis-risk gene Fut2 causes liver disease in mice. Hepatology, 2017, 66: 542-554.
[7] Kummen M, Holm K, Anmarkrud JA, et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut, 2017, 66: 611-619.
[8] Ruhlemann MC, Heinsen FA, Zenouzi R, et al. Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis. Gut, 2017, 66: 753-754.
[9] Iwasawa K, Suda W, Tsunoda T, et al. Characterisation of the faecal microbiota in Japanese patients with paediatric-onset primary sclerosing cholangitis. Gut, 2017, 66: 1344-1346.
[10] Hov JR, Karlsen TH. The Microbiome in Primary Sclerosing Cholangitis: Current Evidence and Potential Concepts. Semin Liver Dis, 2017, 37: 314-331.
[11] Karlsen TH, Folseraas T, Thorburn D, et al. Primary sclerosing cholangitis - a comprehensive review. J Hepatol, 2017, 67: 1298-1323.
[12] Hov JR, Boberg KM, Taraldsrud E, et al. Antineutrophil antibodies define clinical and genetic subgroups in primary sclerosing cholangitis. Liver Int, 2017, 37: 458-465.
[13] Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. J Hepatol, 2017, 66: 1265-1281.
[14] Lazaridis KN, LaRusso NF. Primary Sclerosing Cholangitis. N Engl J Med, 2016, 375: 1161-1170.
[15] Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology, 2009, 50: 808-814.
[16] EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol, 2009, 51: 237-267.
[17] Fickert P, Hirschfield GM, Denk G, et al. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol, 2017, 67: 549-558.
[18] Tabibian JH, Gossard A, El-Youssef M, et al. Prospective Clinical Trial of Rifaximin Therapy for Patients with Primary Sclerosing Cholangitis. Am J Ther, 2017, 24: e56-e63.
[19] Katt J, Schwinge D, Schoknecht T, et al. Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis. Hepatology, 2013, 58: 1084-1093.
[20] Ponsioen C, Arnelo U, Bergquist A, et al. GS-002 - Multicenter randomized trial comparing short-term stenting versus balloon dilatation for dominant strictures in primary sclerosing cholangitis. Journal of Hepatology, 2017, 66: S1-S2.
[21] Trivedi PJ, Scalera I, Slaney E, et al. Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis. J Hepatol, 2017, 67: 957-965.
[22] Trivedi PJ, Tickle J, Vesterhus MN, et al. Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner. Gut, 2017.
[23] Jendrek ST, Gotthardt D, Nitzsche T, et al. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Gut, 2017, 66: 137-144.
[24] Vesterhus M, Holm A, Hov JR, et al. Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. J Hepatol, 2017, 66: 1214-1222. |
